EUVIMEDEUVIMED entdecken
Crossref

Design, Synthesis, and Biological Evaluation of a Potent Dual EZH2–BRD4 Inhibitor for the Treatment of Some Solid Tumors

Niannian Huang, Ping Liao, Yunxia Zuo, Lidan Zhang, Ruotian Jiang iD

Journal of Medicinal Chemistry · 2023

DOI: 10.1021/acs.jmedchem.2c01607 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Niannian Huang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, West China Hospital, Sichuan University, Chengdu 610000, China. Hauptthemen laut MEDLINE: Cell Cycle Proteins, Enhancer of Zeste Homolog 2 Protein, Enzyme Inhibitors, Neoplasms. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Sichuan University, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Enhancer of zeste homolog 2 (EZH2) mediates the trimethylation of histone 3 lysine 27 (H3K27) to promote gene silencing. Inhibition of EZH2 is a viable strategy for cancer treatment; however, only a small subset of hematological malignancies are sensitive to small-molecule EZH2 inhibitors. EZH2 inhibitors cause H3K27 acetylation in most solid tumors, leading to drug resistance. Bromodomain-containing protein 4 (BRD4) inhibitors were reported to enhance the sensitivity of solid tumors to EZH2 inhibitors. Thus, we designed and evaluated a series of dual EZH2-BRD4 inhibitors. ZLD-2, the most promising compound, exhibited potent inhibitory activity against EZH2 and BRD4. Compared to the EZH2 inhibitor GSK126, ZLD-2 displayed potent antiproliferation activity against breast, lung, bladder, and pancreatic cancer cells. In vivo, ZLD-2 exhibited antitumor activity in a BxPC-3 mouse xenograft model, whereas GSK126 promoted tumor growth. Thus, ZLD-2 may be a lead compound for treating solid tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cell Cycle ProteinsEnhancer of Zeste Homolog 2 ProteinEnzyme InhibitorsNeoplasmsTranscription FactorsDrug DesignAntineoplastic AgentsAnimalsHumansMiceCell Line, TumorHistonesNuclear ProteinsBromodomain Containing Proteins

Substanzen

Cell Cycle ProteinsEnhancer of Zeste Homolog 2 ProteinEnzyme InhibitorsHistonesNuclear ProteinsTranscription FactorsAntineoplastic AgentsBRD4 protein, humanBromodomain Containing ProteinsEZH2 protein, human

Autor:innen und Institutionen

  • Department of Anesthesiology, West China Hospital, Sichuan University, Chengdu 610000, China.
  • Laboratory of Anesthesia and Critical Care Medicine, National-Local Joint Engineering Research Center of Translational Medicine of Anesthesiology, West China Hospital, Sichuan University, Chengdu 610000, China.

ORCID-Profile: Ruotian Jiang

Förderung

  • Sichuan University
  • National Natural Science Foundation of China

Zitieren

APA

Huang, N., Liao, P., Zuo, Y., Zhang, L., & Jiang, R. (2023). Design, Synthesis, and Biological Evaluation of a Potent Dual EZH2–BRD4 Inhibitor for the Treatment of Some Solid Tumors. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.2c01607

Vancouver

Huang N, Liao P, Zuo Y, Zhang L, Jiang R. Design, Synthesis, and Biological Evaluation of a Potent Dual EZH2–BRD4 Inhibitor for the Treatment of Some Solid Tumors. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.2c01607

BibTeX
@article{Huang2023,
  author = {Huang, Niannian and Liao, Ping and Zuo, Yunxia and Zhang, Lidan and Jiang, Ruotian},
  title = {Design, Synthesis, and Biological Evaluation of a Potent Dual EZH2–BRD4 Inhibitor for the Treatment of Some Solid Tumors},
  journal = {Journal of Medicinal Chemistry},
  year = {2023},
  doi = {10.1021/acs.jmedchem.2c01607}
}
Kostenlos starten →